bioMérieux receives CE-marking for VIDAS® VITAMIN B12 TOTAL, a blood test to measure total Vitamin B12 concentration

bioMérieux receives CE-marking

for VIDAS^® VITAMIN B₁₂ TOTAL,

a blood test to measure total Vitamin B₁₂ concentration

Marcy-l’Étoile, France, October 15^th, 2024 – bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE-marking of VIDAS^® VITAMIN B₁₂ TOTAL, an automated quantitative test for use on the VIDAS^® immunoassay instruments, for the measurement of total Vitamin B₁₂ concentration in human serum or plasma.

Vitamin B_12, also known as cobalamin, is essential for well-being and cellular metabolism. This micronutrient, mainly present in food products from animal origin – particularly meat, fish, eggs and dairy – is required for normal functioning of the central nervous system, DNA synthesis and healthy red blood cell formation.

Measuring levels of vitamin B₁₂ may help optimize patients’ care since its deficiency can be associated with anemia or neurological symptoms including cognitive difficulties or impaired gait. VIDAS^® VITAMIN B₁₂ TOTAL is an automated quantitative test to aid in the assessment of vitamin B₁₂ status in adults with suspected vitamin B₁₂ deficiency or at risk for low levels of vitamin B₁₂.

This new assay is for use on all VIDAS^® immunoanalysers that provide laboratory personnel with increased throughput and full traceability of test results. VIDAS^® VITAMIN B₁₂ TOTAL completes the VIDAS^® routine test menu, reinforcing the family of assays targeting anemia.

“As it enters a fourth decade, VIDAS^® remains a core focus of the bioMérieux immunoassay strategy with continued R&D investment in new product innovation. VIDAS^® VITAMIN B₁₂ TOTAL perfectly complements our comprehensive VIDAS^® portfolio that also includes infectious diseases, emergency, and critical care assays. The launch of VIDAS^® VITAMIN B₁₂ TOTAL is a testament to bioMérieux’s on-going commitment to provide value-add diagnostic solutions to lab and healthcare professionals for optimized patient care,” commented Jennifer Zinn, Executive Vice President, Clinical Operations, bioMérieux. 

The commercial launch of VIDAS^® VITAMIN B₁₂ TOTAL is planned in select countries at the end of 2024, with an extended rollout in Q1 2025.

ABOUT VIDAS^®

Launched over 30 years ago, VIDAS^® has transformed the field of immunoassays offering laboratories universal access to a simple, automated, and robust technology providing fast and safe results. Today, VIDAS^® is still one of the most widely used immunoassay systems in clinical laboratories worldwide.

The VIDAS^® menu comprises around 100 parameters, including infectious and chronic diseases, as well as a range of tests dedicated to emergency and critical care.

bioMérieux maintains ongoing commitment to the VIDAS^® range, with continual research and new immunoassay solutions to create value for labs and clinicians, benefiting patient care.

ABOUT BIOMÉRIEUX

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2023, revenues reached €3.7 billion, with over 90% of sales outside of France. 

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in  food, pharmaceutical and cosmetic products. www.biomerieux.com.  

bioMérieux is listed on the Euronext Paris stock market.  Symbol: BIM – ISIN Code: FR0013280286

 Reuters: BIOX.PA/Bloomberg: BIM.FP 

CONTACTS

Investor Relations                                                                                                                  

Aymeric Fichet                                                                                     

Tel.: +33 (0)4 78 87 20 00                  investor.relations@biomerieux.com                           

Media Relations                                                                                                                      

bioMérieux                                UNITED STATES                               FRANCE

Romain Duchez                        Liza Deckelbaum (SEEZ)         Laurence Heilbronn (Image 7)

Tel.: +33 (0)4 78 87 20 00         Tel. : (919) 521-0507                     Tel.: +33 (0)1 53 70 74 48 

media@biomerieux.com            lizad@seeztoday.com                   lheilbronn@image7.fr